Tigermed Says Probe Into Major Shareholders Will Not Hit Operations

Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an update.

Hangzhou Tigermed Consulting has issued a clarification following market speculation about whether its controlling shareholders, chairman Ye Xiaoping and director Cao Xiaochun, complied with disclosure rules on past shareholding changes. The company stresses that these matters concern historical equity change disclosures by the two individuals, which it says were publicly announced through prior reduction notices, periodic reports and a brief equity change report.

The company emphasizes that the ongoing regulatory investigation into these historical disclosures does not relate to its underlying business operations and will not affect its normal activities. It also urges shareholders and potential investors to rely solely on official company announcements for information on the group and to exercise caution when trading its shares amid the current scrutiny.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

More about Hangzhou Tigermed Consulting Co., Ltd. Class H

Hangzhou Tigermed Consulting Co., Ltd. is a China-incorporated company listed in Hong Kong and operates through a group structure. It provides professional services to the pharmaceutical and life sciences sectors, positioning itself as a key player in contract research and related consulting for clinical development. The company serves both domestic and international clients through regulated capital market disclosures.

Average Trading Volume: 1,634,388

Technical Sentiment Signal: Sell

Current Market Cap: HK$44.48B

For a thorough assessment of 3347 stock, go to TipRanks’ Stock Analysis page.